



BETA DRUGS LIMITED

BDL/PKL/SEC/2026-27
20th July, 2026

To
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot no. C/I, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai — 400 051.

Subject: Outcome of the Board Meeting held on Monday, 20th July, 2026 – Q1 Results

Dear Sir/Madam,

With reference to above captioned subject matter we would like to inform you that Board of Directors of Beta Drugs Limited in their meeting held today i.e. 20th July, 2026, at 8:00 AM at the Corporate Office of the company situated at SCO-184, Sector-5, Panchkula-134114 has considered and approved the following agenda items:-

1. The un-audited Standalone & Consolidated financial results alongwith limited review report under regulation 33 of SEBI (LODR) Regulation, 2015 for the quarter ended 30th June, 2026.

Pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, we are enclosing herewith the following documents:

1. Management Discussion & Analysis.
2. Limited review Report on Consolidated Financial Results alongwith Un-Audited Consolidated Financial Results for the quarter ended 30th June, 2026.
3. Limited review Report on Standalone Financial Results alongwith Un-Audited Standalone Financial Results for the quarter ended 30th June, 2026.
4. Certificate as per regulation 33(2)(a) of SEBI (LODR) Regulations, 2015

The meeting of the Board of Directors commenced at 8.00 a.m. and concluded at 8:50 a.m.

This is for your information and appropriate dissemination

Thanking You
Your's faithfully
For Beta Drugs Ltd.

Beta Drugs Limited

Company Secretary
ACS - 24684

Rajni Brar
Company Secretary

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com



BETA DRUGS LIMITED

Q1FY27 Results Announcement

Beta Reports Q1FY27 Results — Strong performance across business segments drives superior performance

Beta recorded consolidated total sales of **Rs 125.55 crores** for Q1FY27, a **25.3% increase** from Rs 100.2 crores in the previous fiscal year. The total revenues were Rs. 127.13 crores.

Segmental Performance

Branded oncology: The business continued to deliver stellar performance delivering growth of 47% y-o-y recording sales of INR 33.0 Crores. The growth was on the back of improved performance from existing products and increasing acceptance of our new launches last year.

CMO: Our CMO business delivered robust performance for the quarter and grew by 41% y-o-y on the back of strong traction with our customers and new launches including our proprietary NDDS products in CMO segment. With higher realisations in platins going forward, we expect this business to deliver better performance in FY27.

Exports: Our exports business delivered INR 17.2 Crores in Q1FY27. The business is expected to record a higher growth for the remainder of FY27 as the orders have started to accelerate.

Nivian: Nivian delivered a growth of 45% y-o-y. The higher growth stems from increased penetration and full quarter performance of new products launched in the last quarter of FY26.

Consolidated EBITDA stood at Rs. **28.95 crores** (including other income) and **Rs 27.37 Crores** (excluding other income), with EBITDA margins at **23.06%** (including other income) and **21.80%** in **Q1FY27** (excluding other income). Consolidated EBITDA (excluding other income) grew by **38.9%** y-o-y. Net of Nivian, Beta delivered EBITDA of **INR 24.5 Crores** (excluding other income) demonstrating a growth of 24.5% y-o-y. Improved margins are driven by higher Gross Margins (56.6% in Q1FY27 v/s 50.4% in Q1FY26) on account of change in sales mix towards branded businesses including Nivian. This improvement in EBITDA margins is expected to continue as the business mix moves favourably towards higher contributions from branded and exports.

Beta recorded Net profit of **INR 16.5 Crs.** (net margin: 13.1%) compared to INR 11.7 Crs. in Q1FY26 which shows 40.92% growth. The improvement in Net Profit was on account of reduced finance costs associated with conversion CCDs issued in Nov 2024 and converted in May 2026. The interest cost associated with CCDs was INR 0.75 Crores for Q1FY27 compared to INR 2.1 Crores in Q1FY26.

CIN No.: L24230HP2005PLC028969

Admin. Office: SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) | Phone: +91-172-2585481-482-483
Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, H.P. | Phone No.: 01795-236196
Website: www.betadrugslimited.com | E-Mail: info@betadrugslimited.com



Beta had set out a vision for 2030 which sets a target for accelerated growth and higher margins. We continue to reiterate our expectations in delivering higher growth across our businesses. Our high margin businesses including own branded products and exports are expected to contribute **>80% of the total turnover by 2030**. Beta continues to be one of the fastest-growing players in the Indian branded oncology pharmaceutical market, gaining market share y-o-y and is also emerging a strong innovation focused player. The focus on R&D has led to the launch of differentiated products (NDDS, “first to launch” in India etc.) and strengthened its presence both in India and international markets.

Outlook

We continue to work towards our vision 2030 - a leading formulations company with more than **50% of the turnover coming from own branded products**. We are on track to deliver a 20-25% growth on a consolidated basis for FY27. Our backward integration in KSMs and advanced intermediates is expected to result in strong improvement in our operating margins coupled with change in product mix towards branded business. Nivan will continue to deliver exceptional growth in a fast-growing market through deeper penetration and new product launches. Synergies with Beta are expected to result in higher operating margins for Nivian in FY27 and thereafter. We continue to invest in R&D and have a robust pipeline of NDDS products for launch in FY27 and FY28. This is in addition to new launches where Beta will strive to be either First to Launch / First few to Launch in India.

As the oncology market continues to expand globally, Beta is at the forefront to meet the growing demand for effective cancer treatments in both domestic and international markets.

KHURANA SHARMA & COMPANY

CHARTERED ACCOUNTANTS

H.No. 1299, SECTOR 15-B, CHANDIGARH

PHONE : 9988070254, 9878029920

LIMITED REVIEW REPORT

INDEPENDENT AUDITOR'S REVIEW REPORT ON CONSOLIDATED UNAUDITED QUARTERLY FINANCIAL RESULTS ENDED ON 30th JUNE, 2026 PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)

To,
The Board of Directors
Beta Drugs Limited
Village Nandpur, Lodhimajra Road
Baddi, Distt. Solan
H.P. 174101

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **BETA DRUGS LIMITED** ("the Parent") and its subsidiary ("the Parent" and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax for the quarter ended 30th June, 2026 being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the unaudited results of the subsidiary company: Adley Formulations Pvt Ltd, Adley Lab Limited, Beta Research Private Limited & Nivian Lifesciences Private Limited by management of the Company.

KHURANA SHARMA & COMPANY

CHARTERED ACCOUNTANTS

H.No. 1299, SECTOR 15-B, CHANDIGARH

PHONE : 9988070254, 9878029920

5. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Our conclusion is not modified in respect of this matter.

7. The consolidated unaudited financial results includes the interim unaudited financial information/financial results of Adley Formulations Pvt Ltd (its subsidiary), Adley Lab Limited (its subsidiary) Beta Research Private Limited (its subsidiary) & Nivian Lifesciences Private Limited which have not been reviewed/audited by their auditors, whose interim financial information/ financial results reflect total revenue of Rs. 69,43,89,625.63, Total net profit/(loss) after tax of Rs. 9,86,82,748.93 and total comprehensive income / loss of Rs. Nil, for the Qtr. ended 30th June, 2026, respectively. These financial results whose report have been furnished to us by the management and our opinion on the consolidated financial results in so far as it related to the amount and disclosure included in respect of this subsidiary is based solely on the reports of the management and procedure performed by us as stated in paragraph above.

For KHURANA SHARMA & CO.

Chartered Accountants



Signature

(CA VIBHOR KHURANA)

PARTNER M. NO. 568524

UDIN:

Place: Chandigarh

Date: 20.07.2026

BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

Unaudited Consolidated Financial Results for the quarter ended on 30th June' 2026

Particulars	3 Months Ended on 30.06.2026 (Unaudited)	3 Months Ended on 31.03.2026 (Audited)	3 Months Ended on 30.06.2025 (Unaudited)	Year Ended on 31.03.2026 (Audited)
I. Revenue From Operations	1,25,54,95,637.62	93,96,49,419.38	1,00,20,68,760.18	3,84,82,57,667.32
II. Other Income	1,58,26,052.52	2,89,42,990.53	2,98,80,045.53	11,17,96,551.18
III. Total Revenue (I+II)	1,27,13,21,690.14	96,85,92,409.91	1,03,19,48,805.71	3,96,00,54,218.50
IV. Expenses				
a) Cost of Materials Consumed	50,21,69,267.96	36,78,47,989.52	58,12,46,935.67	1,73,81,43,501.28
b) Purchase of Stock-in-Trade	-	-	-	-
c) (Increase)/Decrease in Stock of Finished Goods/WIP	4,29,95,492.86	(68,85,120.73)	(8,38,18,099.91)	(2,63,45,192.00)
d) Employee benefit expenses	20,39,62,612.58	18,67,78,196.68	16,02,26,014.18	68,00,61,433.74
e) Finance Costs	2,56,25,047.78	3,94,41,751.24	3,32,03,988.69	15,31,10,274.33
f) Depreciation & amortisation expenses	4,34,55,945.35	4,79,72,690.52	3,72,61,277.72	17,15,28,534.10
g) Other expenses	23,26,93,765.13	21,51,22,687.02	14,73,60,542.83	69,96,17,745.86
Total Expenses	1,05,09,02,131.66	85,02,78,194.25	87,54,80,659.18	3,41,61,16,297.31
V. Profit before exceptional and extraordinary items and tax (III-IV)	22,04,19,558.48	11,83,14,215.66	15,64,68,146.53	54,39,37,921.19
VI. Exceptional Items (Pref. Issue)	-	-	-	-
VII. Profit before extraordinary items and tax (V-VI)	22,04,19,558.48	11,83,14,215.66	15,64,68,146.53	54,39,37,921.19
VIII. Extraordinary Items	-	-	-	-
IX. Profit before tax (VII-VIII)	22,04,19,558.48	11,83,14,215.66	15,64,68,146.53	54,39,37,921.19
X. Tax Expenses	5,55,62,303.45	2,78,24,981.70	3,94,82,432.66	12,91,10,952.28
XI. Profit (Loss) for the period from continuing operations (IX-X)	16,48,57,255.03	9,04,89,233.96	11,69,85,713.87	41,48,26,968.91
XII. Profit (Loss) from discounting operations	-	-	-	-
XIII. Tax expenses of discounting operations	-	-	-	-
XIV. Profit (Loss) from discounting operation (after tax) (XII-XIII)	-	-	-	-
XV. Net Profit/(Loss) for the period before NCI (XI+XIV)	16,48,57,255.03	9,04,89,233.96	11,69,85,713.87	41,48,26,968.91
XVI. Non-Controlling Interests	(68,39,006.75)	-	-	-
XVII. Net Profit/(Loss) for the period after NCI (XV+XVI)	15,80,18,248.27	9,04,89,233.96	11,69,85,713.87	41,48,26,968.91
Other comprehensive income				
Items that will not be reclassified to profit or loss				
Gain/(loss) on remeasurement of the defined benefit plans	-	(23,69,628.00)	-	(23,69,628.00)
Income tax on above	-	5,96,387.98	-	5,96,387.98
Items that may be reclassified to profit or loss				
Total Comprehensive Income for the period	15,80,18,248.27	9,22,62,473.98	11,69,85,713.87	41,66,00,208.94
XVI. Earning per share(based on weighted average no. of equity shares)				
a) Basic	14.78	8.93	11.59	40.92
b) Diluted	14.78	8.93	11.59	40.92
XVIII. Paid up equity share capital	11,08,58,720.00	10,13,68,900.00	10,09,45,530.00	10,13,68,900.00

1 The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held on 20th July' 2026.

2 The company is engaged in single business segment i.e. Pharmaceuticals.

3 Figures are regrouped/rearranged, wherever considered necessary.

4 The consolidated financial results include the unaudited financial results of the subsidiaries: Adley Formulations Pvt Ltd, Adley Lab Limited, Beta Research Pvt. Ltd. and Nivian Lifesciences Private Limited.

For KHURANA SHARMA & CO.

Chartered Accountants

(FRN : 010920N)

CA VIBHOR KHURANA

PARTNER

Membership No. : 568524

UDIN:

Place : Chandigarh

Date : 20-07-2026


RAHUL BATRA
 MANAGING DIRECTOR
 DIN : 02229234


RAJNI BRAR
 COMPANY SECRETARY
 ACS24684


NIPUN ARORA
 CFO
 FCA514044

KHURANA SHARMA & COMPANY

CHARTERED ACCOUNTANTS

H.No. 1299, SECTOR 15-B, CHANDIGARH

PHONE : 9988070254, 9878029920

LIMITED REVIEW REPORT

INDEPENDENT AUDITOR'S REVIEW REPORT ON STANDALONE UNAUDITED QUARTERLY FINANCIAL RESULTS FOR PERIOD ENDED ON 30TH JUNE, 2026 PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)

To,
The Board of Directors
Beta Drugs Limited
Village Nandpur, Lodhimajra Road
Baddi, Distt. Solan
H.P. 174101

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **BETA DRUGS LIMITED** ("the Company"), for the quarter ended 30th June, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KHURANA SHARMA & CO.
Chartered Accountants



Signature
(CA VIBHOR KHURANA)
PARTNER M. NO. 568524
UDIN:

Place: Chandigarh
Date: 20.07.2026

BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

Unaudited Standalone Financial Results for the quarter ended on 30th June' 2026

Particulars	3 Months Ended on 30.06.2026 (Unaudited)	3 Months Ended on 31.03.2026 (Audited)	3 Months Ended on 30.06.2025 (Unaudited)	Year Ended on 31.03.2026 (Audited)
I. Revenue From Operations	55,82,57,842.16	54,34,81,394.39	66,32,48,540.41	2,25,42,95,005.63
II. Other Income	1,86,74,222.35	2,91,78,173.84	2,97,48,588.53	11,14,33,642.13
III. Total Revenue (I+II)	57,69,32,064.51	57,26,59,568.23	69,29,97,128.94	2,36,57,28,647.76
IV. Expenses				
a) Cost of Materials Consumed	26,00,36,707.01	22,71,86,737.44	44,83,22,089.03	1,21,90,63,471.79
b) Purchase of Stock-in-Trade	-	-	-	-
c) (Increase)/Decrease in Stock of Finished Goods/WIP	(19,70,443.16)	(18,00,353.53)	(3,88,04,496.44)	51,46,085.00
e) Employee benefit expenses	9,35,68,234.80	9,24,98,000.03	8,47,99,443.69	33,99,05,865.23
f) Finance Costs	1,60,06,075.03	2,87,41,404.85	2,78,75,165.04	11,80,69,397.56
g) Depreciation & amortisation expenses	2,48,50,112.26	2,73,99,545.77	2,03,82,642.42	9,66,93,306.47
h) Other expenses	10,50,63,648.74	12,80,40,411.39	9,38,47,507.17	40,47,35,025.58
Total Expenses	49,75,54,334.68	50,20,65,745.95	63,64,22,350.90	2,18,36,13,151.63
V. Profit before exceptional and extraordinary items and tax (III-IV)	7,93,77,729.83	7,05,93,822.28	5,65,74,778.04	18,21,15,496.13
VI. Exceptional Items (Pref. Issue)	-	-	-	-
VII. Profit before extraordinary items and tax (V-VI)	7,93,77,729.83	7,05,93,822.28	5,65,74,778.04	18,21,15,496.13
VIII. Extraordinary Items	-	-	-	-
IX. Profit before tax (VII-VIII)	7,93,77,729.83	7,05,93,822.28	5,65,74,778.04	18,21,15,496.13
X. Tax Expenses	2,00,42,230.49	1,72,56,548.19	1,42,38,740.91	3,87,70,370.77
XI. Profit (Loss) for the period from continuing operations (IX-X)	5,93,35,499.34	5,33,37,274.09	4,23,36,037.12	14,33,45,125.36
XII. Profit (Loss) from discounting operations	-	-	-	-
XIII. Tax expenses of discounting operations	-	-	-	-
XIV. Profit (Loss) from discounting operation (after tax) (XII-XIII)	-	-	-	-
XV. Net Profit/(Loss) for the period (XI+XIV)	5,93,35,499.34	5,33,37,274.09	4,23,36,037.12	14,33,45,125.36
Other comprehensive income				
Items that will not be reclassified to profit or loss				
Gain/(loss) on remeasurement of the defined benefit plans	-	(21,97,612.00)	-	(21,97,612.00)
Income tax on above	-	5,53,094.99	-	5,53,094.99
Items that may be reclassified to profit or loss				
Total Comprehensive Income for the period	5,93,35,499.34	5,49,81,791.10	4,23,36,037.12	14,49,89,642.37
XVI. Earning per share(based on weighted average no. of equity shares)				
a) Basic	5.55	5.26	4.19	14.14
b) Diluted	5.55	5.26	4.19	14.14
XVIII. Paid up equity share capital	11,08,58,720.00	10,13,68,900.00	10,09,45,530.00	10,13,68,900.00

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held on 20th July' 2026.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.

For KHURANA SHARMA & CO.
Chartered Accountants
(FRN : 010920N)



CA VIBHOR KHURANA
PARTNER
Membership No. : 568524
UDIN:
Place : Chandigarh
Date : 20-07-2026

RAHUL BATRA
MANAGING DIRECTOR
DIN : 02229234

RAJNIBRAR
COMPANY SECRETARY
ACS24684

NIRUN ARORA
CFO
FCA514044



BETA DRUGS LIMITED

BDL/PKL/SEC/2026-27

20th July, 2026

To,
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G
Bandra Kurla Complex
Bandra East
Mumbai 400051


Script:- Certificate as per regulation 33(2) (a) of SEBI (LODR) Regulations, 2015

Dear Sir,

We the undersigned, in our respective capacities as Managing Director and Chief Financial officer of Beta Drugs Limited, certify that the Standalone and Consolidated Unaudited Financial results for the quarter ended 30th June, 2026, do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

Thanking You
Your's faithfully

For Beta Drugs Ltd.


Rahul Batra
Managing Director
DIN: 02229234


Mr Nipun Arora,
Chief Financial Officer

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134-114 Haryana (INDIA) Phone. +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com